Elizabeth Holmes’ Partner Eyes New Blood Testing Company: What You Need to Know
For anyone who follows tech scandals, the name Elizabeth Holmes probably rings a bell. She’s the founder of Theranos, a now-defunct startup that once promised to revolutionize blood testing—but instead became one of Silicon Valley’s biggest cautionary tales. Now, in a surprising twist, her partner Billy Evans is reportedly looking to raise money for a new blood testing startup.
So, what does this mean? Is this just history repeating itself… or something entirely different?
Let’s break it down in simple terms.
Wait—Who Is Billy Evans Again?
Billy Evans is more than just Elizabeth Holmes’ husband. He comes from a wealthy hotel family and is a graduate of MIT. Though he’s kept a fairly low profile until now, recent reports suggest he’s stepping into the startup world himself—specifically, into blood diagnostics.
At first glance, that sounds a lot like deja vu, doesn’t it?
What’s the New Startup All About?
According to TechCrunch, Evans is quietly reaching out to potential investors to support a brand-new health tech company focused on—you guessed it—blood testing. Unlike Theranos, though, this venture is still in the early planning stages, so exact details are sparse.
But here’s what makes it interesting: Some of the people who have been approached say the pitch sounds promising, especially when it comes to improving the accuracy and affordability of diagnostic tests.
Still, for many people, this raises red flags.
Why All the Buzz Around Blood Testing Startups?
Let’s face it—getting blood tests done isn’t anyone’s favorite activity. It’s often time-consuming, expensive, and involves multiple steps: Make an appointment. Travel to a lab. Wait for results.
Wouldn’t it be awesome if we could get fast, inexpensive, and reliable test results from just a finger prick—or maybe even something less invasive?
That’s exactly the dream that Theranos sold. Unfortunately, as we now know, it couldn’t deliver.
So why are people still interested in this space?
Because there’s a real demand for it. And health tech entrepreneurs know that.
How Is This Project Different from Theranos?
That’s the million-dollar question. So far, there are a few things that set this new startup apart:
- New leadership: Billy Evans is at the helm, not Elizabeth Holmes.
- Different approach: The pitch apparently doesn’t promise a miracle device but instead focuses on improving existing technology.
- Smarter strategy: The team may be trying to build trust by being more transparent about its capabilities.
Whether this will be enough to earn investor confidence is still unclear. But let’s be honest—after the collapse of Theranos, this space is under a microscope.
Can Investors Trust a Blood Testing Startup Again?
Trust is tricky when you’re digging out from under the shadow of a scandal. And this one isn’t just any scandal—it was the subject of books, documentaries, and even a TV series.
But let’s slow down and think practically.
Just because someone is connected to a previous company doesn’t mean they’ll repeat the same mistakes. Take Steve Jobs, for example. He got ousted from Apple in the mid-1980s and started a new company, NeXT. Many were skeptical then, too—but years later, Apple acquired NeXT, and Jobs returned stronger than ever.
Could Billy Evans pull off a similar comeback story in the world of blood diagnostics? We’ll have to wait and see.
The Risk Factor: Should We Be Concerned?
In the startup world, risk is part of the game. Especially in health tech.
When you’re dealing with people’s health—life and death stuff—there’s no room for error. That’s why regulatory approvals, lab verifications, and scientific testing are so important.
So the big question becomes: Will this new venture prioritize science over storytelling?
For anyone investing in or using a future product from this startup, that’s what really matters.
What Does This Mean for the Future of Health Tech?
Even with scandals in the rear-view mirror, the healthcare tech industry is still booming. From wearable health monitors to AI-assisted diagnostics and yes—even better blood testing—the landscape is changing fast.
People want:
- Faster test results without the lab runaround
- At-home options for managing chronic conditions
- Affordable healthcare solutions that don’t break the bank
If Evans’ new startup can actually deliver on even one of these promises, it could capture a lot of attention—both from investors and from patients.
Looking Ahead: Caution or Optimism?
So, where do we go from here?
Some folks may be understandably cautious. Once burned, twice shy, as the saying goes. But others might see this as an opportunity. If someone can learn from Theranos’ mistakes—and build something real this time—then maybe it’s worth watching.
The key will be transparency and science-backed claims. Without those, even the best ideas can come crashing down.
As the saying goes, “don’t put old wine in new bottles.”
Final Thoughts
Is the world ready to trust another blood testing startup—especially one with ties to Elizabeth Holmes?
That’s the question hanging in the air right now.
On one hand, innovation in health tech is desperately needed. On the other, credibility is earned, not declared.
Here’s hoping this new venture leads with facts over flash. The last thing anyone wants is another overhyped promise that can’t deliver.
So, what’s your take? Would you trust a new health startup with familiar roots, or are some things better left in the past?
SEO Keywords used naturally:
• Billy Evans blood testing startup
• blood diagnostic technology
• Elizabeth Holmes partner startup
• health tech innovation
• Theranos new venture
• blood testing device
• investment in health startups
Want More Tech News Like This?
Sign up for our newsletter to get future updates on health tech, startup funding, and the stories shaping Silicon Valley—minus the hype.
Stay informed. Stay curious. And as always, read between the headlines.
—
Author’s Note: If this story hit a nerve—or got you thinking—feel free to share your thoughts in the comments below. Let’s keep the conversation going.